^
    1d
    PRIMAVERA: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. (clinicaltrials.gov)
    P1/2, N=161, Recruiting, AstraZeneca | N=110 --> 161 | Trial completion date: May 2026 --> Apr 2029 | Trial primary completion date: May 2026 --> Apr 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    1d
    EZHiSWITCH: Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. (clinicaltrials.gov)
    P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    Trial initiation date
    |
    ARID1A (AT-rich interaction domain 1A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    Ezharmia (valemetostat)
    2d
    A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Kyowa Kirin, Inc. | N=34 --> 72
    Enrollment change • Trial initiation date • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive
    2d
    HX009-II-02: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting --> Completed | N=99 --> 48 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HX-009
    3d
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=56, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jan 2028 --> Apr 2028 | Trial primary completion date: Jan 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    6d
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK negative
    |
    cyclophosphamide • vincristine • prednisone • aclarubicin
    6d
    Study of Tazemetostat in Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=6, Terminated, University of Alabama at Birmingham | N=30 --> 6 | Trial completion date: Dec 2029 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Mar 2026; Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to increased risk of secondary malignancies in subjects.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tazverik (tazemetostat)
    7d
    DR-01-ONC-001: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Dren Bio | N=69 --> 200
    Enrollment change • First-in-human
    |
    DR-01
    8d
    Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders. (PubMed, Am J Surg Pathol)
    Multiplex single-molecule fluorescence ISH confirmed the presence of MCPyV in CD4+ T-cells. These findings support the hypothesis that MCPyV infection is specifically associated with rare CD4+ T-cell lymphomas, particularly in transplant recipients.
    Journal
    |
    CD4 (CD4 Molecule)
    9d
    EBV-positive CD8 + peripheral T-cell lymphoma in the post-transplant setting: case report and review of the literature. (PubMed, J Hematop)
    Biopsy of a spinal lesion demonstrated a T-cell lymphoma with diffuse EBV positivity and CD8 expression. The patient's disease was refractory to conventional chemotherapy with persistent/recurrent disease in other organ systems showing the aggressive nature of this disease and limited efficacy of standard regimens.
    Review • Journal
    |
    CD8 (cluster of differentiation 8)
    9d
    ADAPT-HEM: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Beijing Biotech
    New P1/2 trial • IO biomarker
    |
    cyclophosphamide • fludarabine IV
    14d
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)